NCT05553496 is a Phase 2, PHASE3 clinical trial of Rituximab in Pharmacological Action, sponsored by Ain Shams University.

Who is sponsoring NCT05553496?

NCT05553496 is sponsored by Ain Shams University.

What drugs are being tested in NCT05553496?

Interventions in NCT05553496: Rituximab, Dexamethasone.

What condition does NCT05553496 study?

NCT05553496 studies Pharmacological Action.

Is NCT05553496 still recruiting?

NCT05553496 is currently status unknown. Last updated 23 September 2022.

Last reviewed 2022-09-23 · How we verify

NCT05553496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

Status unknown Phase 2, PHASE3 Last updated 23 September 2022

What this trial tests

Phase 2, PHASE3 trial testing Rituximab in Pharmacological Action in 40 participants. Status unknown.

Timeline

25 September 2022

Primary endpoint
1 April 2023

1 October 2023

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	25 September 2022
Primary completion	1 April 2023
Estimated completion	1 October 2023

Drugs / interventions tested

Rituximab — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Pharmacological Action — all drugs for Pharmacological Action →

Sponsor

Ain Shams University

Who can join

18 and older, any sex, with Pharmacological Action. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Pharmacological Action

Currently open trials in the same condition.

NCT06324370 — Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) · NA · active not recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05553496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 23 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05553496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing